Uprifosbuvir (MK-3682) is an antiviral drug developed for the treatment of hepatitis C. It is a nucleotide analogue which acts as an NS5B RNA polymerase inhibitor. As of 2019 it was in Phase III human clinical trials. [1][2][3]

2017年9月29日 · the investigational combination regimens MK-3682B (grazoprevir/ruzasvir/ uprifosbuvir) and MK-3682C (ruzasvir/uprifosbuvir) for the treatment of chronic hepatitis C virus (HCV) infection. This decision was made based on a review of available Phase 2 efficacy data and in consideration of

2022年8月16日 · A simple and efficient process to prepare Uprifosbuvir intermediate, 2′-deoxy-α-2′-chloro-β-2′-methyluridine (1), from bis-pivaloyl tertiary alcohol 5a is described. The key discoveries are a novel BSA-promoted anhydrouridine formation catalyzed by HCl as an additive and a milder safe Me 2 SiCl 2 -promoted chlorination of anhydrouridine.

This study is an open-label, multi-center trial to evaluate the novel 2-drug regimen of uprifosbuvir (MK-3682) 450 mg and ruzasvir (MK-8408) 60 mg in participants with chronic hepatitis C virus (HCV) genotype (GT)1, GT2, GT3, GT4, GT5, or GT6 infection.

乌磷布韦（英语：Uprifosbuvir，MK-3682）是一种开发用于治疗丙型肝炎的抗病毒药物。 它是一种 核苷酸 类似物，可用作 NS5B RNA聚合酶 抑制剂，目前处于III期人体 临床试验 中。

2017年5月4日 · 作者研究了磷酰氯化合物 1 与核苷 2 的反应，以组装成核苷类前药mk-3682（ 3 ，图2）。这是一种丙型肝炎病毒（hcv）ns5b病毒的rna聚合酶抑制剂，目前在临床试验中用于治疗hcv感染。

2021年6月28日 · Uprifosbuvir (MK-3682) is an antiviral drug developed for the treatment of Hepatitis C. It is a nucleotide analogue which acts as an NS5B RNA polymerase inhibitor. It is currently in Phase III human clinical trials .

描述了一种从双新戊酰叔醇5a制备 Uprifosbuvir 中间体 2'-脱氧-α-2'-氯-β-2'-甲基尿苷 ( 1 ) 的简单有效的方法。 关键发现是一种由 HCl 作为添加剂催化的新型 BSA 促进的脱水尿苷形成，以及一种更温和、安全的 Me 2 SiCl 2促进脱水尿苷的氯化反应。 这些发现共同促成了针对化合物1的稳健过程的建立，这在工厂规模上得到了成功证明。 A simple and efficient process to prepare Uprifosbuvir intermediate, 2′-deoxy-α-2′-chloro-β-2′-methyluridine (), from bis-pivaloyl tertiary alcohol is …

Uprifosbuvir is under investigation in clinical trial NCT02332707 (Efficacy and Safety of Grazoprevir (MK-5172) and Uprifosbuvir (MK-3682) With Elbasvir (MK-8742) or Ruzasvir (MK-8408) for Chronic Hepatitis C Genotype (GT)1 and GT2 Infection (MK-3682-011)).